Calcineurin inhibitors were discontinued by 40%, thiopurines by 31.6%, anti-TNFα antibodies by 24.5%, vedolizumab by 15.7%, JAK inhibitors by 15.4%, and ustekinumab by 13.1% of patients after the COVID-19 diagnosis (Figure 2A). This evidence concerns the gene TNF and COVID-19.